AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients

AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
  • AstraZeneca Plc AZN reported initial results from the TROPION-Lung02 phase 1b trial showing that datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab with or without platinum chemotherapy demonstrated promising clinical activity and a tolerable safety profile in non-small cell lung cancer (NSCLC) without actionable genomic alterations. 
  • Datopotamab deruxtecan is jointly developed by Daiichi Sankyo DSKNY and AstraZeneca.
  • The interim analysis demonstrated an overall response rate in the overall population of 37% in patients receiving datopotamab deruxtecan plus Merck & Co Inc's Keytruda (pembrolizumab) (doublet therapy).
  • The data showed an ORR of 41% in patients receiving datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy (triplet therapy). 
  • A disease control rate (DCR) of 84% was seen with doublet and triplet combination therapy.
  • In previously untreated patients, ORRs of 62% (on doublet therapy) and 50% (on triplet therapy) were observed. 
  • Eight partial responses (PRs) were seen in patients receiving doublet therapy, and 10 PRs (three pending confirmation) were seen in patients receiving triplet therapy. 
  • A DCR of 100% was observed with doublet therapy and 90% with triplet therapy.
  • Price Action: AZN shares are up 0.81% at $65.65 during the premarket session on the last check Tuesday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral